rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

MannKind Corporation

MNKD · Nasdaq

Health CarePharmaceuticalsNot moving yet

MNKD stood above a rising 150-day average in 18 of the last 52 weekly readings, and has been out of that trend for the last 34 weeks. It is 11.3% below that average now. Pharmaceuticals: 32% of its 74 stocks in an uptrend (−7 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 34
Industry in uptrend
32% -7 in 4 wk
Insider buys, 12 months
$518K
Insider sales, 12 months
$4.3M
Officials’ trades on record
0
Institutions holding
243 (+7)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 18 of 52 weeks.

20 Apr – 19 Oct
26%34%43%Apr 26Jun 26Jul 26Sep 26Oct 26

Pharmaceuticals: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$2.0M$0$425KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months14
Buyers · sellers1 · 5
WhoDidSharesTraded
Steven B. BinderDirectorsold39,051at $3.2925 Sep 2026filed 28 Sep 2026
Steven B. BinderDirectorsold33,558at $3.8110 Sep 2026filed 14 Sep 2026
Steven B. BinderDirectorsold39,051at $4.067 Aug 2026filed 10 Aug 2026
Steven B. BinderDirectorsold52,485at $4.0617 Jul 2026filed 17 Jul 2026
David ThomsonEVP Genl Counsel & Secretarysold24,109at $4.0517 Jul 2026filed 17 Jul 2026
David ThomsonEVP Genl Counsel & Secretarysold3,033at $3.2912 May 2026filed 13 May 2026
Steven B. BinderDirectorsold16,940at $3.2912 May 2026filed 13 May 2026
Michael CastagnaChief Executive Officerbought100,000at $2.5910 Mar 2026filed 10 Mar 2026
Stuart A. TrossChief People & Workpl Officersold47,006at $6.338 Jan 2026filed 9 Jan 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders243+7 on the quarter
New · exited52 · 44
Reported value$781.3M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 202632,133,223$136.9M+3,532,225+12.4%
Rubric Capital Management LPadded · filed 14 Aug 202618,000,000$76.7M+14,379,587+397.2%
STATE STREET CORPreduced · filed 7 Aug 202616,174,043$68.9M-2,509,440−13.4%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 202613,169,392$56.1M+278,326+2.2%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20267,947,203$33.9M+442,056+5.9%
WELLINGTON MANAGEMENT GROUP LLPadded · filed 14 Aug 20267,844,807$33.4M+4,561,628+138.9%
Frazier Life Sciences Management, L.P.added · filed 14 Aug 20266,600,000$28.1M+700,000+11.9%
Deep Track Capital, LPnew · filed 14 Aug 20266,000,000$25.6M+6,000,000
180 WEALTH ADVISORS, LLCadded · filed 7 Jul 20264,959,351$21.1M+667,648+15.6%
FMR LLCadded · filed 13 Aug 20264,101,046$17.5M+620,082+17.8%
31 Mar 2023 – 30 Jun 2026
157199240Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Steven B. Binder Company insiderDirector · last 25 Sep 20269 · 16
David Thomson Company insiderEVP Genl Counsel & Secretary · last 17 Jul 20260 · 70
Christopher B. Prentiss Company insiderChief Financial Officer · last 15 Jul 20260 · 0
Dominic Marasco Company insiderPres, Endocrine Business Unit · last 15 Jul 20260 · 0
Michael Castagna Company insiderChief Executive Officer · last 15 Jul 202622 · 22
Sanjay R. Singh Company insiderEVP Technical Operations · last 15 Jul 20260 · 1
Stuart A. Tross Company insiderChief People & Workpl Officer · last 15 Jul 202613 · 5
Anthony C. Hooper Company insiderDirector · last 20 May 20261 · 0
Christine Mundkur Company insiderDirector · last 20 May 20261 · 0
James Samuel Shannon Company insiderDirector · last 20 May 20260 · 0
Jennifer Grancio Company insiderDirector · last 20 May 20261 · 0
Michael A. Friedman Company insiderDirector · last 20 May 20260 · 0

Same industry

ABBV AbbVieLeading+19%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202592.3%
Operating profit marginFY 2025 · to 31 Dec 202511.1%
Free cash flow marginFY 2025 · to 31 Dec 20253.9%
Return on capital employedFY 2025 · to 31 Dec 20256.2%
Cash conversionFY 2025 · to 31 Dec 2025311%
Share count trendFY 2025 · to 13 Feb 20260.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$74.9M
Free cash flowFY 2025 · to 31 Dec 2025$13.7M

Analyst forecasts

No analyst forecasts yet.